Hyperlipidaemia

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

EMA approval · 2026-01-09
EMA Authorised: Praluent (alirocumab) — Sanofi Winthrop Industrie
The European Medicines Agency has authorised Praluent (alirocumab) for dyslipidaemias, with Sanofi Winthrop Industrie as the marketing autho…